Fusen Pharmaceutical Company Limited

SEHK:1652 Rapporto sulle azioni

Cap. di mercato: HK$665.4m

Fusen Pharmaceutical Gestione

Gestione criteri di controllo 2/4

Fusen Pharmaceutical Il CEO è Dudu Cao, nominato in Jan2013, e ha un mandato di 11.83 anni. la retribuzione annua totale è CN¥ 5.00M, composta da 32.4% di stipendio e 67.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 20.92% delle azioni della società, per un valore di HK$ 139.19M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.6 anni e 7.6 anni.

Informazioni chiave

Dudu Cao

Amministratore delegato

CN¥5.0m

Compenso totale

Percentuale dello stipendio del CEO32.4%
Mandato del CEO11.8yrs
Proprietà del CEO20.9%
Durata media del management5.6yrs
Durata media del Consiglio di amministrazione7.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

May 21
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Mar 31
Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Dec 14
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

Sep 02
Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Apr 02
Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

Mar 06
A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Feb 08
We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Jan 18
Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Dec 28
Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Dec 07
What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Nov 20
If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dudu Cao rispetto agli utili di Fusen Pharmaceutical?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-CN¥90m

Mar 31 2024n/an/a

-CN¥63m

Dec 31 2023CN¥5mCN¥2m

-CN¥36m

Sep 30 2023n/an/a

-CN¥24m

Jun 30 2023n/an/a

-CN¥11m

Mar 31 2023n/an/a

-CN¥23m

Dec 31 2022CN¥2mCN¥2m

-CN¥35m

Sep 30 2022n/an/a

-CN¥34m

Jun 30 2022n/an/a

-CN¥34m

Mar 31 2022n/an/a

-CN¥9m

Dec 31 2021CN¥2mCN¥2m

CN¥17m

Sep 30 2021n/an/a

CN¥48m

Jun 30 2021n/an/a

CN¥79m

Mar 31 2021n/an/a

CN¥75m

Dec 31 2020CN¥2mCN¥1m

CN¥70m

Sep 30 2020n/an/a

CN¥67m

Jun 30 2020n/an/a

CN¥65m

Mar 31 2020n/an/a

CN¥59m

Dec 31 2019CN¥548kCN¥516k

CN¥53m

Sep 30 2019n/an/a

CN¥63m

Jun 30 2019n/an/a

CN¥72m

Mar 31 2019n/an/a

CN¥87m

Dec 31 2018CN¥251kCN¥242k

CN¥102m

Compensazione vs Mercato: La retribuzione totale di Dudu ($USD 689.83K ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 233.55K ).

Compensazione vs guadagni: La retribuzione di Dudu è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Dudu Cao (38 yo)

11.8yrs

Mandato

CN¥4,997,000

Compensazione

Mr. Zhiming Cao, also known as Dudu Cao is the Executive Director and Chief Executive Officer of Fusen Pharmaceutical Company Limited since January 18, 2013 and serves as its Chairman since November 04, 20...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Zhiming Cao
CEO & Executive Chairman11.8yrsCN¥5.00m20.92%
HK$ 139.2m
Taisheng Hou
Executive Directorno dataCN¥81.00kNessun dato
Yongsheng Chi
Executive Directorno dataCN¥78.00kNessun dato
Qingfen Meng
Executive Directorno dataCN¥62.00kNessun dato
Zhen Li
Chief Financial Officer5.6yrsNessun datoNessun dato
Yuk Hong Yeung
Company Secretaryless than a yearNessun datoNessun dato

5.6yrs

Durata media

52.5yo

Età media

Gestione esperta: Il team dirigenziale di 1652 è esperto e expertise (durata media dell'incarico 5.6 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Zhiming Cao
CEO & Executive Chairman11.8yrsCN¥5.00m20.92%
HK$ 139.2m
Taisheng Hou
Executive Director7.6yrsCN¥81.00kNessun dato
Yongsheng Chi
Executive Director7.6yrsCN¥78.00kNessun dato
Qingfen Meng
Executive Director7.6yrsCN¥62.00kNessun dato
Kwok Tung Lee
Independent Non-Executive Director5.6yrsCN¥162.00kNessun dato
Wing Chun Sze
Independent Non-Executive Director6.4yrsCN¥162.00kNessun dato
Kit Wa To
Independent Non-Executive Director4.3yrsCN¥162.00kNessun dato

7.6yrs

Durata media

56yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1652 sono considerati esperti (durata media dell'incarico 7.6 anni).